CN111110584A - Skin care composition with moisturizing and anti-aging effects and preparation method thereof - Google Patents
Skin care composition with moisturizing and anti-aging effects and preparation method thereof Download PDFInfo
- Publication number
- CN111110584A CN111110584A CN201911272852.5A CN201911272852A CN111110584A CN 111110584 A CN111110584 A CN 111110584A CN 201911272852 A CN201911272852 A CN 201911272852A CN 111110584 A CN111110584 A CN 111110584A
- Authority
- CN
- China
- Prior art keywords
- skin care
- care composition
- percent
- skin
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 29
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000004973 liquid crystal related substance Substances 0.000 claims abstract description 27
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 26
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims abstract description 17
- 241000270295 Serpentes Species 0.000 claims abstract description 17
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 17
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims abstract description 16
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims abstract description 16
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 16
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 15
- 239000008367 deionised water Substances 0.000 claims abstract description 15
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 15
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 15
- 235000019437 butane-1,3-diol Nutrition 0.000 claims abstract description 13
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940032094 squalane Drugs 0.000 claims abstract description 13
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 13
- 239000000230 xanthan gum Substances 0.000 claims abstract description 13
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 13
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 13
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 12
- 229960001631 carbomer Drugs 0.000 claims abstract description 12
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 10
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960005323 phenoxyethanol Drugs 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 33
- 238000002156 mixing Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 11
- 230000032683 aging Effects 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- YDSVPIYLRFZLAT-UHFFFAOYSA-N C(C)(=O)O.C(C)(=O)O.NC(CCC(=O)NCC1=CC=CC=C1)N Chemical compound C(C)(=O)O.C(C)(=O)O.NC(CCC(=O)NCC1=CC=CC=C1)N YDSVPIYLRFZLAT-UHFFFAOYSA-N 0.000 claims description 6
- 108010016626 Dipeptides Proteins 0.000 claims description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
- 238000004945 emulsification Methods 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 3
- WUYKDJNJIXDTAO-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O WUYKDJNJIXDTAO-UHFFFAOYSA-N 0.000 claims 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
- FYYQZWIXRQJNAC-RMAOKOMNSA-N NCCC(N(C[C@@H](C1)O)[C@@H]1C(C(C1=CC=CC=C1)NC(CCC(N)N)=O)=O)=O Chemical compound NCCC(N(C[C@@H](C1)O)[C@@H]1C(C(C1=CC=CC=C1)NC(CCC(N)N)=O)=O)=O FYYQZWIXRQJNAC-RMAOKOMNSA-N 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 15
- 239000003998 snake venom Substances 0.000 abstract description 8
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 abstract description 4
- 239000012466 permeate Substances 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 79
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 23
- 230000037303 wrinkles Effects 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 14
- 239000000306 component Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 9
- 239000010410 layer Substances 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 6
- -1 acetyl glutaminyl Chemical group 0.000 description 5
- 239000004909 Moisturizer Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 230000004118 muscle contraction Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002884 skin cream Substances 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- CDQPEEPFBFKZEM-UHFFFAOYSA-N CCCC(=O)NC(N)(N)c1ccccc1 Chemical compound CCCC(=O)NC(N)(N)c1ccccc1 CDQPEEPFBFKZEM-UHFFFAOYSA-N 0.000 description 2
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 1
- ZHUJMSMQIPIPTF-JMBSJVKXSA-N (2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZHUJMSMQIPIPTF-JMBSJVKXSA-N 0.000 description 1
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- RRSSMGPWRZSFER-UHFFFAOYSA-N 4,4-diamino-N-benzylbutanamide Chemical compound NC(N)CCC(=O)NCC1=CC=CC=C1 RRSSMGPWRZSFER-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 241000271042 Gloydius halys Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 241001477931 Mythimna unipuncta Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 101800002700 Waglerin-1 Proteins 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940059958 centella asiatica extract Drugs 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940064064 purslane extract Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000037339 smooth wrinkles Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The application provides a skin care composition with moisturizing and anti-aging effects, which comprises the following components in percentage by weight: 1-5% of 1, 3-butanediol, 0.01-5% of hyaluronic acid, 0.01-0.5% of xanthan gum, 0.01-1% of carbomer, 0.01-6% of squalane, 0.1-5% of liquid crystal emulsifier, 0.1-5% of emulsifying aid, 0. 80.0001-4% of acetyl hexapeptide, 0.0001-10% of snake venom-like peptide, 0.1-1% of phenoxyethanol, 0.2-0.6% of citric acid and the balance of deionized water, wherein the pH value of the skin care composition is 5.0-8.0. The active ingredient acetyl hexapeptide-8 and the snake venom like peptide are wrapped in a net structure by adopting the liquid crystal structure emulsifier, so that the technical problem of instability of the snake venom like peptide is solved, and the release speed of the snake venom like peptide can be controlled. Realizes synergistic effect, thereby improving the anti-aging effect. The anti-aging active ingredients can effectively permeate the skin and stay in the skin for a long time, so that the long-acting anti-aging effect is achieved.
Description
Background
Skin aging is a complex series of biological processes within the skin tissue, and is the result of the combined action of all endogenous physiological factors and exogenous environmental factors. Furthermore, the programmed regulation of genetic gene codes, the influence of related aging genes and protein expression levels, long-term large-dose sunlight ultraviolet irradiation and the like are one of the important factors causing the natural aging and photoaging of skin. Whatever the factor leading to skin aging, it not only affects normal skin tissue structure and physiological function, but also directly affects the appearance and appearance of the outer layer of skin. Therefore, skin aging is almost a major enemy of beauty-seeking defense. The facial beautifying and skin anti-aging preparation and the beautifying cosmetics thereof are one of the products which are best sold and favored in the global market, and can make the skin plump and elastic by moisturizing and moisturizing the skin, and can improve the skin aging rhythm to a certain extent. At present, various skin moisturizing and anti-aging cosmetics with various formulations are developed. The main functional components, bioactive substances, natural medicinal monomers and the like in the cosmetics for face beauty and skin anti-aging are used. Most of the active biological polypeptide skin moisturizers are skin moisturizers (hyaluronic acid, hyaluronan, chitosan and the like), skin barrier repair agents (ceramide, phospholipid, cholesterol and the like), skin nutrients (protein, amino acid, polysaccharide and the like), and active biological polypeptide and facial beautification and skin anti-aging research and application are increasingly intensive, and the active biological polypeptide skin moisturizers, the skin beautification, the skin care and health care and the skin anti-aging research and application values of the active biological polypeptide skin moisturizers, the skin care and health care and the skin anti-aging research and application values are continuously researched and proved.
The development process of the skin care product is the discovery and utilization process of active substances, and the snake venom-like peptide is a substance which is discovered in recent years and has the functions of removing wrinkles and resisting aging. Chinese patent CN106038351A discloses a polypeptide composition for lightening wrinkles, comprising: a polypeptide composition for lightening wrinkles, comprising: and) selecting one or more polypeptides that inhibit acetylcholine release by preventing vesicle fusion with the cell membrane, including but not limited to pentapeptide-18, acetyl hexapeptide-3, acetyl glutaminyl heptapeptide-1. Chinese patent CN108852894A discloses a polypeptide composition for repairing, whitening and removing wrinkles, which is characterized in that the polypeptide composition for repairing, whitening and removing wrinkles comprises the following components in percentage by weight: a repair polypeptide combination (0.001% -0.5%), the supplemental polypeptide combination comprising palmitoyl tetrapeptide-7 and tripeptide-1-copper; a supplemental collagen polypeptide combination (0.001% -0.3%) comprising palmitoyl tripeptide-1, palmitoyl tripeptide-5, palmitoyl pentapeptide-4; wrinkle-removing polypeptide composition (0.001% -0.5%), which comprises acetyl hexapeptide-8, snake venom peptide and melittin; a skin lightening polypeptide combination (0.001% -0.5%), comprising nonapeptide-1, carnosine, tetrapeptide-30; the skin care composition comprises a plurality of small molecule active substances, a plurality of skin care active agents, a plurality of pH regulators and a plurality of auxiliary agents, and the balance of water, wherein the repair polypeptide composition, the collagen polypeptide supplement composition, the wrinkle removing polypeptide composition and the skin brightening polypeptide composition account for 0.001-1% of the total mass.
Chinese patent CN108785186A discloses a polypeptide skin-beautifying youth essence, which comprises the following components in parts by weight: 70g of water, 0.02g of EDTA disodium, 5g of glycerol, 3g of propylene glycol, 0.08g of xanthan gum, 0.2g of allantoin, 1g of hyaluronic acid, 0.1g of nipagin methyl ester, 0.5g of D-panthenol, 0.2g of oat B-glucan, 0.1g of HPS0, 0.02g of incense, 0.1g of MTI0, 1g of centella asiatica extract, 0.1g of snake venom peptide, 80.1g of hexapeptide, 120.1g of decapeptide, 0.1g of oligopeptide-3 (Lumixyil), 0.1g of oryzanol peptide and 1g of purslane extract. The patent generally adopts a plurality of active ingredients, and the corresponding skin care product with the efficacy is prepared by simply superposing the known effects of the active ingredients. However, active ingredients are prone to failure and the addition of a large number of components can affect the efficacy of the active ingredient to some extent.
Chinese patent CN108078876A discloses a hydrogel preparation, which comprises the following components by weight percent: 2-30 wt% of a skin conditioner comprising a snake venom polypeptide as a core component, 5-25 wt% of a moisturizing agent, 4-6 wt% of a film forming agent, 0.01-10 wt% of an antioxidant, 0.005-2 wt% of a chelating agent, 0.01-2 wt% of a cooling agent, 0.01-1 wt% of a pH adjusting agent, 0.001-0.5 wt% of a flavoring agent, and the balance deionized water, wherein the snake venom polypeptide is embedded in the hydrogel scaffold structure by crosslinking. The special patent can effectively solve the problem that the snake venom polypeptide is easily decomposed and damaged by an oxidizing agent, a reducing agent, a proteolytic enzyme and the like. However, the method is still cumbersome to prepare and the range of application is limited by the gel.
The prior art studies on specific snake venom-like peptides have been in the use stage of their own action, and intensive studies on how to more effectively utilize the active ingredients have been required.
Disclosure of Invention
Based on the defects in the prior art, the invention aims to provide a skin care composition with moisturizing and anti-aging effects, solves the technical problem of instability of snake venom-like peptide, and can control the release rate of the snake-like peptide.
Another object of the present invention is to provide a simple method for preparing a skin care composition with moisturizing and anti-aging effects, which does not require complicated treatment of active ingredients and is not limited to the preparation of skin care products in special states, and can be applied to skin care compositions including but not limited to essence, facial masks, creams, emulsions, and gels.
In order to achieve the purpose, the invention adopts the technical scheme that: the skin care composition with the effects of moisturizing and resisting aging comprises the following components in percentage by weight:
the skin care composition has a pH of 5.0-8.0.
Further, the skin care composition with the moisturizing and anti-aging effects comprises the following components in percentage by weight:
the skin care composition has a pH of 6.0-7.0.
Further, the skin care composition with the moisturizing and anti-aging effects comprises the following components in percentage by weight:
the skin care composition has a pH of 6.3 to 6.7.
Further, the snake venom-like peptide is selected from one or more of dipeptide diaminobutyrylbenzylamide diacetate and β -alanyl hydroxy prolyl diaminobutyrylbenzylamide.
Further, the liquid crystal emulsifier is selected from one or more of Arlatone 2121, Montanov68 and Olivem 1000.
Further, the emulsification aid is selected from one or more of hexadecanol and octadecanol.
Further, the skin care composition also contains 0.01-0.05% of essence.
Further, the skin care composition has a liquid crystal structure.
A preparation method of a skin care composition with moisturizing and anti-aging effects comprises the following steps:
(1) mixing 1, 3-butanediol, hyaluronic acid and xanthan gum, and uniformly stirring and dispersing to obtain a phase A;
(2) mixing carbomer and squalane, uniformly stirring at the heating temperature of 70-80 ℃, then cooling to 50-60 ℃, adding the phase A, and uniformly stirring to obtain a phase B;
(3) mixing acetyl hexapeptide-8 and snake venom-like peptide to obtain phase C;
(4) and (3) putting the liquid crystal emulsifier and the emulsifying auxiliary agent into an emulsifying pot, heating to 85-100 ℃, stirring, homogenizing for 5-10 minutes, uniformly stirring, cooling to 40-60 ℃, adding the phase C, and uniformly stirring to obtain the phase D.
(5) Heating deionized water to 40-50 deg.C, sequentially adding phase A, phase B, phenoxyethanol, and phase D, stirring, adding citric acid, and adjusting pH to 6.5-6.8.
Further, the rotation speed of the stirring is 40-70 rpm.
Further, the essence is added in step (5).
The adopted acetyl hexapeptide-8 can block muscle contraction signals, relax muscles, reduce the depth of wrinkles caused by muscle contraction, smooth wrinkles, prevent the generation of wrinkles, effectively tighten aging and relax skin, promote cell regeneration, improve aging skin, and effectively remove wrinkles, repair and resist aging.
The snake venom-like peptide simulates the action mechanism of polypeptide component Waglerin-1 in venom of Weishi armyworm Agkistrodon Halys, is a 22-amino acid peptide which selectively binds to Ach receptors (nAChPs) and acts on postsynaptic membranes, is a reversible nACh R antagonist, and can prevent Ach from being combined with the receptors by being combined with small subunits of nAChP, so that the snake venom-like peptide inhibits muscle contraction, can reduce muscle contraction frequency, and has excellent smoothing and quick wrinkle removing effects.
The liquid crystal emulsifier molecules are associated to form a layered structure, the layered structure has a multi-layer network structure, and a large amount of bound water is contained between layers. The lamellar liquid crystal structure contains hydrophilic groups and hydrophilic groups, and the structure can hold a large amount of bound water and can form a hydrophobic continuous phase, so that the skin care product with the liquid crystal structure can wrap active ingredients, and the release rate of the ingredients can be slowed down or formed. Meanwhile, the lamellar liquid crystal structure can be attached to the surface of the skin, and the permeation of active ingredients on the surface layer of the skin is promoted.
The simple liquid crystal emulsifier cannot form a complete liquid crystal structure to a certain extent, and the compounding of the emulsifying aid can be effectively combined with the liquid crystal emulsifier, so that the formation of the liquid crystal structure is facilitated and a larger liquid crystal structure unit is formed.
The 1, 3-butanediol can prevent the loss of the moisture of the horny layer of the epidermis and absorb the moisture in the air at the same time, thereby achieving the effect of promoting the skin to moisturize.
The hyaluronic acid has excellent moisturizing and hydrating effects, and can promote proliferation and differentiation of epidermal cells, remove oxygen free radicals, promote nutrition supply of skin, and achieve whitening and freckle removing effects.
Squalane is mild and safe, is not greasy and thick, has good skin-friendly property and good permeability, can be highly dissolved with sebum secreted by skin, promotes effective components of the skin cream to permeate into skin cells, can form a stable skin lipid film on the surface of the skin, prevents the loss of skin moisture, improves the skin moistening property and air permeability of the skin cream, improves the elasticity, softness and plumpness of the skin, promotes blood microcirculation, enhances the metabolism of cells, improves the elasticity of the skin cream, improves the wrinkle phenomenon, and has the functions of removing wrinkles and resisting aging.
Compared with the prior art, the invention has the following beneficial effects:
(1) the invention adopts the liquid crystal structure emulsifier to wrap the active ingredient acetyl hexapeptide-8 and the snake venom-like peptide in a net structure, solves the technical problem of instability of the snake-like peptide and can control the release speed of the snake-like peptide. Realizes synergistic effect, thereby improving the anti-aging effect. The anti-aging active ingredients can effectively permeate through the skin and stay in the skin for a long time, so that the long-acting anti-aging effect is achieved.
(2) The active ingredients of the skin care composition can quickly penetrate into the skin epidermis, and provide instant moisturizing effect for the skin and the effect of lasting moisture retention.
(3) The preparation method is simple and easy to implement, is not limited to a special state, and can be widely applied to skin care products, such as emulsion, cream, essence, facial masks and the like.
Drawings
FIG. 1 is a graph showing the cumulative sustained release of snake venom-like peptide dissolved in water acetyl hexapeptide-8 in phase D of examples 1-3 and comparative example 1.
FIGS. 2-5 are polarization microscope observations of the skin care compositions prepared in examples 1-3 and comparative example 1.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Example 1
A skin care composition with moisturizing and anti-aging effects comprises the following components in percentage by weight: 1, 3-butanediol, 2% of hyaluronic acid, 0.5% of xanthan gum, 1% of carbomer, 6% of squalane, Arlatone 21212%, 1.5% of hexadecanol, 81% of acetyl hexapeptide, 5% of dipeptide diaminobutyryl benzylamide diacetate, 0.5% of phenoxyethanol, 0.4% of citric acid and the balance of deionized water; the skin care composition has a pH of 6.5.
A preparation method of a skin care composition with moisturizing and anti-aging effects comprises the following steps:
(1) mixing 1, 3-butanediol, hyaluronic acid and xanthan gum, and uniformly stirring and dispersing to obtain a phase A;
(2) mixing carbomer and squalane, stirring at 70 deg.C, cooling to 54 deg.C, adding phase A, and stirring to obtain phase B; (3) mixing acetyl hexapeptide-8 and dipeptide diaminobutyrylbenzylamide diacetate to obtain phase C; (4) placing Arlatone 2121 and hexadecanol in an emulsifying pot, heating to 85 deg.C, stirring, homogenizing for 10 min, cooling to 40 deg.C, adding phase C, and stirring to obtain phase D;
(5) heating deionized water to 50 deg.C, sequentially adding phase A, phase B, phenoxyethanol, and phase D, stirring, adding citric acid, and adjusting pH to 6.5.
Example 2
A skin care composition with moisturizing and anti-aging effects comprises the following components in percentage by weight: 2% of 1, 3-butanediol, 1% of hyaluronic acid, 0.2% of xanthan gum, 0.7% of carbomer, 4% of squalane, 685% of Montanov, 1.6% of octadecanol, 81% of acetyl hexapeptide, 3% of dipeptide diaminobutyryl benzylamide diacetate, 1% of phenoxyethanol, 0.6% of citric acid and the balance of deionized water; the skin care composition has a pH of 6.8. A preparation method of a skin care composition with moisturizing and anti-aging effects comprises the following steps:
(1) mixing 1, 3-butanediol, hyaluronic acid and xanthan gum, and uniformly stirring and dispersing to obtain a phase A;
(2) mixing carbomer and squalane, stirring at 80 deg.C, cooling to 55 deg.C, adding phase A, and stirring to obtain phase B;
(3) mixing acetyl hexapeptide-8 and dipeptide diaminobutyrylbenzylamide diacetate to obtain phase C;
(4) placing Montanov68 and octadecanol in an emulsifying pot, heating to 90 deg.C and stirring, homogenizing for 6 min, cooling to 45 deg.C, adding phase C and stirring to obtain phase D.
(5) Heating deionized water to 45 deg.C, sequentially adding phase A, phase B, phenoxyethanol, and phase D, stirring, adding citric acid, and adjusting pH to 6.8.
Example 3
A skin care composition with moisturizing and anti-aging effects comprises, by weight, 2% of 1, 3-butanediol, 5% of hyaluronic acid, 0.1% of xanthan gum, 0.1% of carbomer, 3% of squalane, Olivem 10003.4%, 2% of an emulsifying aid, 80.8% of acetyl hexapeptide, 4% of β -alanyl hydroxy prolyl diamino butyryl benzylamide, 0.7% of phenoxyethanol, 0.4% of citric acid and the balance of deionized water, wherein the pH value of the skin care composition is 6.7.
A preparation method of a skin care composition with moisturizing and anti-aging effects comprises the following steps:
(1) mixing 1, 3-butanediol, hyaluronic acid and xanthan gum, and uniformly stirring and dispersing to obtain a phase A;
(2) mixing carbomer and squalane, stirring at 706 deg.C, cooling to 53 deg.C, adding phase A, and stirring to obtain phase B;
(3) mixing acetyl hexapeptide-8 and β -alanyl hydroxy prolyl diamino butyryl benzyl amide to obtain phase C;
(4) placing Olivem 1000 and hexadecanol in an emulsifying pot, heating to 100 deg.C and stirring, homogenizing for 10 min, cooling to 60 deg.C, adding phase C, and stirring to obtain phase D.
(5) Heating deionized water to 58, sequentially adding phase A, phase B, phenoxyethanol and phase D, stirring, adding citric acid, and adjusting pH to 6.7.
Comparative example 1
Comparative example 1 was the same as example 1 in composition and preparation method, except that comparative example 1 used non-liquid crystal emulsifier glyceryl stearate instead.
Performance testing
1. The skin care compositions prepared in examples 1 to 3 and comparative example 1 were observed under a polarization microscope. Test results show that the skin care product prepared by the invention has a liquid crystal structure; in contrast, comparative example 1, in the absence of a liquid crystal emulsifier, no liquid crystal structure was observed.
2. 4 healthy female testers with the age of 25-35 years and the same indexes as much as possible are selected to perform the test under the environment of room temperature (23 +/-2) DEG C and humidity of 30-50%. Before the test, the volunteer needs to be calmed for 20min in the environment, after the environment is balanced, experimental areas of 4cm multiplied by 4cm are drawn on the left forearm and the right forearm respectively, the interval of the areas is at least 1cm, and the left arm and the right arm of the test subject are smearing areas of samples to be tested. The test sites of examples 1-3 and comparative example 1 were applied to 1-4 female test subjects, respectively. The test subjects used a skin moisture tester to test the moisture content of the test sites 3 hours after application of the cosmetics. The test results are reported in table 1.
TABLE 1
The data in table 1 are the average values of the corresponding indexes before trial and after 3h of test; the moisture of the horny layer reflects the water content of the horny layer of the skin, and the more sufficient the moisture of the horny layer of the skin is, the larger the value is; the transdermal water loss value reflects the rate of the skin deep water loss through the skin, and the better the skin stratum corneum barrier moisturizing function is, the smaller the value is; the P value is less than or equal to 0.05, and the difference between the value before trial use and the value after trial use is considered to be significant.
From this, it was found that the skin care composition had excellent moisturizing effect.
3. The D phase in step (4) of examples 1-3 and comparative example 1 was dissolved in deionized water, acetyl hexapeptide-8, and a snake venom-like peptide sustained release profile. Measuring the absorbance of acetyl hexapeptide-8 and snake-like poison peptide at different time by an ultraviolet spectrophotometer, taking deionized water as blank control, calculating the concentration of acetyl hexapeptide-8 and snake-like poison peptide at different time, and drawing the slow release curve of acetyl hexapeptide-8 and snake-like poison peptide cumulative release concentration (%) -time (min). Wherein curves 1-4 correspond to the sustained release curves of examples 1-3 and comparative example 1, respectively.
It is derived from the sustained release curve that the phase D obtained in the process of the invention has good sustained release effect in water, while comparative example 1 releases most of acetyl hexapeptide-8, snake-like poison peptide after dissolving in water, and has no sustained release property. Therefore, the acetyl hexapeptide-8 and the snake venom-like peptide treated by the liquid crystal emulsifier can continuously release active ingredients, and the active ingredients are effectively wrapped by the reticular structure of the liquid crystal emulsifier to play a role in sustained and controlled release, so that the effects of fading fine wrinkles and improving aging are played for a long time.
4. 40 healthy female testers with the ages of 25-35 years and the same indexes as much as possible are selected, and are averagely divided into 4 groups, and the skin care product compositions of examples 1-3 and comparative example 1 are correspondingly used. The product is applied to face after washing face in the morning and evening, and is used continuously for 30 days. The wrinkles and skin elasticity of the eyes and the corners were observed every day, and finally the wrinkles and skin elasticity were rated by the testers, and the rating results were recorded in tables 2 and 3.
TABLE 2
| Wrinkle (wrinkle) | Elasticity of skin | |
| Example 1 | 8 | 9 |
| Example 2 | 9 | 9 |
| Example 3 | 9 | 8 |
| Comparative example 1 | 6 | 7 |
A larger value indicates a greater degree of wrinkle reduction and better skin elasticity. From the above results, the skin care composition of the present invention has excellent effects of reducing wrinkles and improving skin elasticity, and has excellent anti-aging effects. The skin care composition of comparative example 1 also had anti-aging efficacy to some extent, but the effect was significantly worse than that of the present application.
It will be understood by those skilled in the art that the foregoing is only a preferred embodiment of the present invention, and is not intended to limit the invention, and that any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (10)
1. The skin care composition with the effects of moisturizing and resisting aging is characterized by comprising the following components in percentage by weight:
1, 3-butanediol 1-5%
Hyaluronic acid 0.01-5%
Xanthan gum 0.0.01-0.5%
Carbomer 0.01-1%
0.01 to 6 percent of squalane
0.1 to 5 percent of liquid crystal emulsifier
0.1 to 5 percent of emulsification assistant
Acetyl hexapeptide-80.0001-4%
0.0001-10% of snake venom-like peptide
0.1 to 1 percent of phenoxyethanol
Citric acid 0.2-0.6%
Balance of deionized water
The skin care composition has a pH of 5.0-8.0.
2. The skin care composition according to claim 1, comprising the following components in percentage by weight:
2-4% of 1, 3-butanediol
1 to 5 percent of hyaluronic acid
Xanthan gum 0.1-0.5%
Carbomer 0.1-1%
1 to 6 percent of squalane
1 to 5 percent of liquid crystal emulsifier
1 to 5 percent of emulsification assistant
Acetyl hexapeptide-80.01-1%
0.01-5% of snake venom-like peptide
0.5 to 1 percent of phenoxyethanol
Citric acid 0.3-0.6%
Balance of deionized water
The skin care composition has a pH of 6.0-7.0.
3. The skin care composition according to claim 1, comprising the following components in percentage by weight:
2.5 to 3.5 percent of 1, 3-butanediol
Hyaluronic acid 2-4%
Xanthan gum 0.2-0.4
Carbomer 0.5-0.8%
3 to 5 percent of squalane
3 to 4 percent of liquid crystal emulsifier
2 to 3 percent of emulsification assistant
Acetyl hexapeptide-80.1-1%
0.1-4% of snake venom-like peptide
0.6 to 0.8 percent of phenoxyethanol
Citric acid 0.3-0.4%
Balance of deionized water
The skin care composition has a pH of 6.3 to 6.7.
4. The skin care composition of claim 1, wherein the snake venom-like peptide is selected from the group consisting of dipeptide diaminobutyrylbenzylamide diacetate, β -alanylhydroxyprolinyl diaminobutyrylbenzylamide.
5. The skin care composition of claim 1 wherein the liquid crystal emulsifier is selected from one or more of Arlatone 2121, Montanov68, Olivem 1000.
6. The skin care composition according to claim 1, wherein the emulsification aid is selected from one or more of cetyl alcohol and stearyl alcohol.
7. The skin care composition according to claims 1-6, wherein said skin care composition further comprises 0.01-0.05% of a fragrance.
8. The skin care composition according to claims 1-6, wherein the skin care composition has a liquid crystal structure.
9. A method for preparing the skin care composition with moisturizing and anti-aging effects according to claims 1-6, comprising the following steps:
(1) mixing 1, 3-butanediol, hyaluronic acid and xanthan gum, and uniformly stirring and dispersing to obtain a phase A;
(2) mixing carbomer and squalane, uniformly stirring at 70-80 ℃, cooling to 50-60 ℃, adding the phase A, and uniformly stirring to obtain a phase B;
(3) mixing acetyl hexapeptide-8 and snake venom-like peptide to obtain phase C;
(4) putting the liquid crystal emulsifier and the emulsifying auxiliary agent into an emulsifying pot, heating to 85-100 ℃, stirring, homogenizing for 5-10 minutes, uniformly stirring, cooling to 40-60 ℃, adding the phase C, and uniformly stirring to obtain a phase D;
(5) heating deionized water to 40-50 deg.C, sequentially adding phase A, phase B, phenoxyethanol, and phase D, stirring, adding citric acid, and adjusting pH to 6.5-6.8.
10. A method of preparing a skin care composition according to claim 8 wherein the agitation is at a speed of 40 to 70 rpm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911272852.5A CN111110584A (en) | 2019-12-12 | 2019-12-12 | Skin care composition with moisturizing and anti-aging effects and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911272852.5A CN111110584A (en) | 2019-12-12 | 2019-12-12 | Skin care composition with moisturizing and anti-aging effects and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111110584A true CN111110584A (en) | 2020-05-08 |
Family
ID=70499833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911272852.5A Pending CN111110584A (en) | 2019-12-12 | 2019-12-12 | Skin care composition with moisturizing and anti-aging effects and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111110584A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112353705A (en) * | 2020-11-25 | 2021-02-12 | 广东丸美生物技术股份有限公司 | Cosmetic composition, preparation method thereof and cosmetic with wrinkle removing and aging delaying effects |
| CN113116742A (en) * | 2021-04-29 | 2021-07-16 | 山东优杰生物科技有限公司 | Composite polypeptide anti-wrinkle composition and preparation method and application thereof |
| CN113520923A (en) * | 2021-07-21 | 2021-10-22 | 西北农林科技大学 | Liquid crystal cream facial mask containing lees extract and preparation method thereof |
| CN113975187A (en) * | 2021-11-02 | 2022-01-28 | 安徽瀚海博兴生物技术有限公司 | Wrinkle-removing skin care product containing polypeptide amino acid composition and preparation method thereof |
| CN114886792A (en) * | 2022-06-30 | 2022-08-12 | 水羊化妆品制造有限公司 | Wrinkle-removing composition, preparation method and application thereof |
| CN114917156A (en) * | 2022-05-16 | 2022-08-19 | 珠海市医健生物技术研发中心 | Composite anti-aging cold-blended skin cream and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130243712A1 (en) * | 2010-11-30 | 2013-09-19 | Amorepacific Corporation | Cosmetic composition for whitening and improving the resilience of skin |
| CN108498364A (en) * | 2017-02-24 | 2018-09-07 | 上海凡因生物科技有限公司 | Liquid crystal cutaneous permeable agent and its preparation and the application in anti-aging cosmetics |
-
2019
- 2019-12-12 CN CN201911272852.5A patent/CN111110584A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130243712A1 (en) * | 2010-11-30 | 2013-09-19 | Amorepacific Corporation | Cosmetic composition for whitening and improving the resilience of skin |
| CN108498364A (en) * | 2017-02-24 | 2018-09-07 | 上海凡因生物科技有限公司 | Liquid crystal cutaneous permeable agent and its preparation and the application in anti-aging cosmetics |
Non-Patent Citations (1)
| Title |
|---|
| 周梦: "高效复合液晶乳化剂的开发及应用", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112353705A (en) * | 2020-11-25 | 2021-02-12 | 广东丸美生物技术股份有限公司 | Cosmetic composition, preparation method thereof and cosmetic with wrinkle removing and aging delaying effects |
| CN113116742A (en) * | 2021-04-29 | 2021-07-16 | 山东优杰生物科技有限公司 | Composite polypeptide anti-wrinkle composition and preparation method and application thereof |
| CN113520923A (en) * | 2021-07-21 | 2021-10-22 | 西北农林科技大学 | Liquid crystal cream facial mask containing lees extract and preparation method thereof |
| CN113520923B (en) * | 2021-07-21 | 2023-04-07 | 西北农林科技大学 | Liquid crystal cream facial mask containing lees extract and preparation method thereof |
| CN113975187A (en) * | 2021-11-02 | 2022-01-28 | 安徽瀚海博兴生物技术有限公司 | Wrinkle-removing skin care product containing polypeptide amino acid composition and preparation method thereof |
| CN114917156A (en) * | 2022-05-16 | 2022-08-19 | 珠海市医健生物技术研发中心 | Composite anti-aging cold-blended skin cream and preparation method thereof |
| CN114886792A (en) * | 2022-06-30 | 2022-08-12 | 水羊化妆品制造有限公司 | Wrinkle-removing composition, preparation method and application thereof |
| CN114886792B (en) * | 2022-06-30 | 2024-05-14 | 水羊化妆品制造有限公司 | Wrinkle-removing composition, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111110584A (en) | Skin care composition with moisturizing and anti-aging effects and preparation method thereof | |
| CN113616566B (en) | Skin care essence for tightening skin and preparation method thereof | |
| KR20180123036A (en) | Composition for moisturizing and use thereof | |
| CN110664644B (en) | Skin care composition containing folic acid, essence and preparation method thereof | |
| CN109394645B (en) | Smearing type water acupuncture essence and preparation method thereof | |
| CN111450010A (en) | Composition with anti-aging effect and application thereof in cosmetics | |
| CN111297760B (en) | Composition with repairing effect and application thereof | |
| CN114931543B (en) | Repairing and anti-aging essence with high content of blue copper peptide and preparation method thereof | |
| CN106074304A (en) | A kind of containing hyaluronate sodium microsphere and the anti-aging cosmetics compositions with smooth out wrinkles, even skin effect of peptide | |
| CN115105453A (en) | Skin care product with antibacterial, anti-inflammatory and repairing functions and preparation method thereof | |
| CN112294666A (en) | Silica gel eye cream with permeation promoting function | |
| CN115400034A (en) | Moisturizing and repairing essence milk and preparation method thereof | |
| CN111991286A (en) | Eye cream composition for fading fine wrinkles and preparation method thereof | |
| CN111568797A (en) | Composition for quickly removing fine lines and application thereof | |
| CN111588650B (en) | Repairing composition, repairing mask liquid and repairing mask | |
| KR102582633B1 (en) | Cosmetic composition for skin regeneration and wrinkle improvement containing epidermal growth factor liposomes and growth factor complex | |
| JPS63150209A (en) | Skin cosmetic | |
| CN114983856B (en) | Blue copper peptide solution with penetration promoting system and preparation method and application thereof | |
| CN113730289B (en) | Eye and lip care composition with multiple repairing effects and application thereof | |
| CN113786361B (en) | Eye cream composition with pouch removing effect and preparation method thereof | |
| CN114557909A (en) | Multiple peptide anti-wrinkle essence and preparation method thereof | |
| CN113181070A (en) | A skin caring cream with wrinkle removing and antiaging effects, and its preparation method | |
| CN113116742A (en) | Composite polypeptide anti-wrinkle composition and preparation method and application thereof | |
| CN112190501A (en) | Silk essence capable of protecting hair and hands simultaneously and preparation method thereof | |
| CN113440443A (en) | Moisturizing composition, application thereof, essence and moisturizing mask |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200508 |